1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Behcet Disease - Drugs In Development, 2022, provides an overview of the Behcet Disease (Cardiovascular) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Behcet disease (BEH-chets), sometimes called Behcet syndrome, Morbus Behçet, or Silk Road disease, is a rare immune-mediated systemic vasculitis. The more common symptoms include sores in the mouth and on the genitals (sex organs). More serious symptoms can include inflammation (swelling, heat, redness, and pain) in the eyes and other parts of the body. The goal of treatment is to reduce pain and prevent serious problems.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Behcet Disease - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Behcet Disease (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Behcet Disease (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Behcet Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 1 and 2 respectively.
Behcet Disease (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Behcet Disease (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Behcet Disease (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Behcet Disease (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Behcet Disease (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Behcet Disease (Cardiovascular)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Behcet Disease (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Behcet Disease (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Behcet Disease - Overview
- Behcet Disease - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Behcet Disease - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Behcet Disease - Companies Involved in Therapeutics Development
- Amgen Inc
- Aristea Therapeutics Inc
- Iltoo Pharma
- Kangpu Biopharmaceuticals Ltd
- Pharmapraxis
- Behcet Disease - Drug Profiles
- adalimumab biosimilar - Drug Profile
- Product Description
- Mechanism Of Action
- aldesleukin - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- apremilast - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- KPG-612 - Drug Profile
- Product Description
- Mechanism Of Action
- RIST-4721 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Behcet Disease - Dormant Projects
- Behcet Disease - Discontinued Products
- Behcet Disease - Product Development Milestones
- Featured News & Press Releases
- Feb 27, 2020: CHMP recommended extensions of indication for Otezla
- Jul 19, 2019: FDA approves OTEZLA (apremilast) for the treatment of oral ulcers associatd with Behcet’s Disease
- Feb 17, 2018: OTEZLA (Apremilast) Phase III Data Showed Significant Improvements in Patients with Active Behcet's Disease with Oral Ulcers
- Apr 15, 2015: Phase II Data for Apremilast in Behçet's Disease Published in The New England Journal of Medicine
- Jun 14, 2013: Celgene Presents Results From Phase II Trial Of Oral Apremilast In Patients With Behçet’s Disease At EULAR
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Behcet Disease, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Behcet Disease - Pipeline by Amgen Inc, 2022
- Behcet Disease - Pipeline by Aristea Therapeutics Inc, 2022
- Behcet Disease - Pipeline by Iltoo Pharma, 2022
- Behcet Disease - Pipeline by Kangpu Biopharmaceuticals Ltd, 2022
- Behcet Disease - Pipeline by Pharmapraxis, 2022
- Behcet Disease - Dormant Projects, 2022
- Behcet Disease - Discontinued Products, 2022
- Number of Products under Development for Behcet Disease, 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Targets, 2022
- Number of Products by Stage and Targets, 2022
- Number of Products by Mechanism of Actions, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Amgen Inc
- Aristea Therapeutics Inc
- Iltoo Pharma
- Kangpu Biopharmaceuticals Ltd
- Pharmapraxis
